Ataxia UK Stresses Urgent Action on Friedreich’s Ataxia Treatment Access

Ataxia UK has issued a press release today highlighting the urgent need for access to omaveloxolone (Omav), the only approved treatment for Friedreich’s ataxia (FA). Despite MHRA approval, people in England, Wales and Northern Ireland are still waiting, while in Scotland a pathway exists for clinicians to apply for early access on a case-by-case basis. The medicine is available for patients in the US and Europe. This inequality cannot continue. We are calling on the Department of Health and Social Care to work with us, clinicians, and the FA community on a temporary compassionate access programme before more time is lost.

Ataxia UK Stresses Urgent Action on Friedreich’s Ataxia Treatment Access